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Objective:  Chronic  hepatitis  B  virus  infection  is one  of  the  most  serious  infections  and  a  major
risk  factor  for  deaths  from  cirrhosis  and  liver  cancer.  We  estimate  age-,  sex-  and  region-speciﬁc
prevalence  of  chronic  HBV  infection  and  calculate  the  absolute  number  of  persons  being  chronically
infected.
Methods:  A  systematic  review  of  the  literature  for  studies  reporting  HBV  infection  was  conducted  and
worldwide  HBsAg  seroprevalence  data  was  collected  over  a 27-year  period  (1980–2007).  Based  on
observed  data,  age-speciﬁc  prevalence  and  endemicity  were  estimated  on  a global  level  and  for  all  world
regions  for  1990  and  2005  using  an  empirical  Bayesian  hierarchical  model.
Findings: From  1990  to 2005,  the  prevalence  of  chronic  HBV  infection  decreased  in  most  regions.  This  was
particularly  evident  in  Central  sub-Saharan  Africa,  Tropical  and  Central  Latin  America,  South  East  Asia
and  Central  Europe.  Despite  this  decrease  in prevalence,  the  absolute  number  of  HBsAg  positive  persons
increased  from  223  million  in 1990  to 240  million  in  2005.  Age-speciﬁc  prevalence  varied  by  geographical
region  with  highest  endemicity  levels  in  sub-Saharan  Africa  and  prevalence  below  2%  in  regions  such  as
Tropical  and  Central  Latin  America,  North  America  and  Western  Europe.  Asian  regions  showed  distinct
prevalence  patterns  with  lower  intermediate  prevalence  in  South  Asia,  but  up  to  8.6%  HBsAg  prevalence
in  East  Asia.  Strong  declines  were  seen  in  South  East  Asian  children.
Conclusion: Declines  in  HBV  infection  prevalence  may  be  related  to expanded  immunization.  The  increas-
ing  overall  number  of  individuals  being  chronically  infected  with  HBV,  and  the  widespread  global
differences  in  HBV  prevalence  call for targeted  approaches  to tackle  HBV-related  mortality  and  mor-
bidity.  HBV  infection  prevalence  data  are  needed  at  country  and  sub-national  level  to  estimate  disease
burden  and  guide  health  and  vaccine  policy.. Introduction
Knowledge of region- and age-speciﬁc prevalence of hepatitis
 infection is important for evaluating vaccination programs and
ational disease prevention and control efforts. Furthermore, any
odeling and assessment of the disease burden associated with the
epatitis B virus (HBV) requires prevalence estimates. So far, global
tudies on HBV seroprevalence are limited and comprehensive data
re not available for many countries. In addition, demographic
hanges and expanded vaccination can create new epidemiological
atterns of the virus which impact on region-speciﬁc endemicity
evels.
HBV is spread predominantly by percutaneous or mucosal expo-
ure to infected blood and other body ﬂuids with numerous forms
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of human transmission. The sequelae of HBV infection include acute
and chronic infection, cirrhosis of the liver and primary liver can-
cer. The likelihood of progression to chronic infection is inversely
related to age at the time of infection. Around 90% of infants infected
perinatally become chronic carriers, unless vaccinated at birth. The
risk for chronic HBV infection decreases to 30% of children infected
between ages 1 and 4 years and to less than 5% of persons infected
as adults [1,2].
Chronic  HBV infection progresses nonlinearly through 3–4
phases, from the immune-tolerant phase to immune clearance or
immunoactive phase, to nonreplicative inactive phase and possible
reactivation [3,4]. After infection with HBV, most patients either
develop immunity (87–90%) and clear the infection or become
chronic carriers. A lower percentage will develop liver disease or
Open access under CC BY-NC-ND license.chronic active hepatitis with an increased risk of developing cir-
rhosis, liver cancer or both [5]. The fatality of these diseases as well
as their attribution to hepatitis infection is well known: 600,000
HBV-related deaths were estimated to occur annually [6] and 73%
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linear time trend; and an offset for data on males. Second, for each
time period (1980–1996 and 1997–present), sex, and region (of 21
world regions), Dismod ﬁts a Bayesian model using all data in thatJ.J. Ott et al. / Vacci
f all liver cancer deaths worldwide are due to hepatitis viruses,
ith much higher proportions in low and middle income countries
7].
The complex serology and natural history associated with HBV
nfection creates challenges for the assessment of HBV prevalence
nd the provision of comparable global estimates. This is due to
he availability of multiple laboratory markers for hepatitis B infec-
ion. Antibodies and antigens associated with this infection include
epatitis B surface antigen (HBsAg), antibody to hepatitis surface
ntigen (anti-HBs), antibody to hepatitis B core antigen (anti-HBc),
nd IgM antibody subclass of anti-HBc (IgM anti-HBc). Some studies
lso report markers of high HBV replication such as hepatitis B “e”
ntigen (HBeAg), antibody to HBeAg (anti-HBe), and quantitative
BV-DNA.
HBsAg is the main clinical marker indicating acute or chronic
nfection and prevalence as well as endemicity of HBV infection
s deﬁned by the presence of HBsAg [8]. HBsAg testing is the
rimary way to identify persons with chronic HBV infection and
everal characteristics of this serological marker increase the pre-
ision of HBsAg estimates, including high speciﬁcity, long serum
ersistence, low possibility of chronic cases losing HBsAg [3,8,9].
owever, routine population surveillance of chronic viral hepati-
is is currently rare. Standardized monitoring would help not only
n quantifying the disease burden on a population level but also
n determining the characteristics of infected individuals, avoid-
ng further transmission and allocating appropriate treatment. This
s particularly important for populous countries that have been
reviously categorized as highly endemic for chronic hepatitis B
nfection such as China, Indonesia, Nigeria and parts of Africa and
sia, where an immense absolute number of people live with the
irus [6,8]. However, up to date region-speciﬁc and globally com-
arable chronic HBV prevalence data are lacking and no relevant
eta-analysis has been published on this topic. In addition, the
bsolute number of individuals being chronically infected with HBV
s not known.
In  the light of this gap, the objective of our study is to estimate
ge- and region speciﬁc HBsAg prevalence in 1990 and 2005 by con-
ucting a systematic review and modeling HBsAg prevalence. This
nvestigation is part of the Global Burden of Diseases, Injuries, and
isk Factors Study, which carries out complete systematic assess-
ents of global data on disease and risk factors in order to produce
omparable estimates for two time periods, 1990 and 2005.
We  provide detailed HBsAg prevalence estimates that are cate-
orized by the 21 regions as deﬁned by the Global Burden of Disease
tudy and geographically mapped by endemicity level. The Global
urden of Disease regions are based on geographic regions or con-
inents and are grouped based on child and adult mortality levels
nd major causes of death in each country (see Section 2).
.  Methods
.1. Systematic review
A  systematic review of published literature and data was  con-
ucted to identify articles reporting prevalence of hepatitis B, C, and
 virus infection for all countries over a 27-year period, from 1980
o 2007. Articles published in this time frame were included regard-
ess of when the data were collected. Within each database, medical
ubject heading terms and freetext search terms were included to
dentify article abstracts that contained (1) a term related to the
epatitis B, C or D virus or their markers of hepatitis infection and
2) a term related to either prevalence, incidence, or disease burden
search terms available by request from the author). Results were
estricted to original research articles in English. Abstracts were
creened and were required to report hepatitis B or C prevalence2012) 2212– 2219 2213
or  incidence. Where abstracts were incomplete or missing, the full-
text article was  retrieved and reviewed manually to determine if
it reported prevalence of hepatitis B or C virus infection. A total of
6064 English citations were found (3273 Medline, 2283 Embase,
508 Cinhal). Review articles, outbreak investigations and national
infections disease notiﬁcation reports were excluded since they
provide information on incident or acute cases. Data reported in
the article had to be reasonably representative of the general pop-
ulation rather than conducted among a special high-risk group (i.e.
injecting drug users, HIV-positive individuals) or a population that
was  selected based on a risk factor for viral hepatitis or a condition
associated with hepatitis infection (Fig. 1, exclusion criteria).
After  applying manual de-duplication and the exclusion criteria
on the abstract, 1233 articles were obtained (references are listed
in Web  Annex 1). These were further screened for the speciﬁed
exclusion criteria and for HBsAg as the marker of interest in the full
text before country-speciﬁc prevalence information was extracted.
For one country, the United States (US), a representative primary
national data source was  available and data were included only
from articles reporting prevalence from the National Health and
Nutrition Examination Survey (NHANES) [10,11].1
Articles only reporting HCV marker (222) and those reporting
summary or other markers of HBV (82) were excluded; 396 articles
were determined to meet all eligibility criteria.
2.2. Analysis and modeling of data
Age-, sex- and country-speciﬁc HBsAg seroprevalence data were
extracted. Additional information obtained was: primary author,
year of publication, number of individuals tested for HBsAg, lab-
oratory test/method, and study year. If the year was missing, two
years prior to publication was assumed as the study year. In case
age was not further speciﬁed, it was imputed based on contextual
information such that pregnant women and those giving birth were
assumed to be 15–49 years, army recruits and soldiers between 18
and 45 years, blood and organ donors between 17 and 65 years,
and school children between 5 and 15 years. Extracted data were
grouped according to 21 Global Burden of Disease Regions (Web
Annex 2) and assigned a quality rating based on population size,
sampling and representativeness of the general population. Using
the extracted study seroprevalence data, prevalence of HBsAg was
modeled using Dismod III v3.0, a generic disease modeling system
[12]. DisMod III aims to synthesize data to generate estimates of the
disease burden associated with more than 200 diseases and over
20 major risk factors for the Global Burden of Disease 2010 study
[13]. DisMod III models multiple disease parameters, including inci-
dence, prevalence, remission, and mortality, in order to ensure
consistency among the parameters. Data on each of these parame-
ters are synthesized using a hierarchical empirical Bayesian model
to make estimates for 21 world regions based on observed data in
each modeled region, data observed in other regions, and data from
other time periods (by estimating a time trend). Brieﬂy, Dismod
III ﬁrst ﬁts an empirical prior estimate separately for each disease
parameter (e.g., prevalence and incidence). The empirical prior has
the following elements: geographic hierarchy, in which estimates
for each region are informed by data from the same region and (to
a lesser extent) data from other regions; a ﬂexible age pattern; a1 The deﬁnition of chronic HBV infection and the respective marker used slightly
varied  by period of survey conduction. From 1988 on, HBV  infection was deﬁned as
the presence of anti-HBc and HBsAg. We  have included this estimate since all HBsAg
positive individuals should be expected to have anti-HBc.
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Total num ber  of  English  ci tations 
having Hepatitis  B,  C,  or  D indicator in  
title or  ab stract: 6064  
Citations meeting initial  search  criteria 
after abstr act  screened:  1233 
Exclus ion  due to   
- dup licati on (1396 ) 
- abstr act  no t report ing  prevalen ce, in ciden ce or  he patitis  marker  
(1950) 
- abstract  repo rts  hepatitis  ma rker but stu dy type and  quali ty not appropriate  
(surveillance  and  case  repor ts, missing  den omi nator,  sele ction  
based on  hepa titis  case)  (14 39)  
- high  risk  groups  (pris oners,  lympho ma and  rheu matolog y 
ass ociated  with he patitis,  li ver and  stomach  cancer  pati ents) 
- revi ews (42)  and  arti cles  not accessible  (4 ) 
Exc lus ion  due to 
- article  not  re porting  HBV  or  HCV  marker  (HDV  re porting  on ly 
dropped),  hi gh risk  groups included  (374),  fr om mul tiple  reg ion s (18), 
immigrant po pula tions  (33)  and  adop tees (2) 
Articles meeting  expa nded  se arch 
criteria  and including  re levant markers 
(HBV and  HCV): 80 6 
Articles only reporti ng HCV  marker  (2 23),  or  HBV  marker  among  HCV-
positive in divi duals  (1 ) 
Articles re ad and  abstr act ed for HBV: 
582 
Articles re port ing  HBV  mark er other  than  HBsAg  or  HBV  marker 
not further  sp ecified  but ment ion ed as  cate gory (82) 
Articles re ad and  abstr act ed for 
HBsAg : 
500 
Articles excluded  after  additi onal  exclus ion  criteria*  ap pli ed in  full  text  
(104)  
Articles meet ing  all inclusion crit eria : 
396 
Fig. 1. Flowchart of article screening.
*Additional  exclusion criteria applied in full text screening and not identiﬁed as such during ﬁrst article review.
(a)  Populations of persons at high risk for hepatitis including those with diseases related to HBV such as acute (viral) hepatitis cases, liver cancer, and cirrhosis; HIV-positives.
(b) Other high risk study populations and highly deﬁned populations such as prisoners, HIV/STD clinic attendees indicating recently acquired sexually transmitted disease,
sex  workers, multi-transfused patients, drug addicted individuals and injecting drug users, liver transplant recipients, refugees, homeless people.
(c) Reports  of acute diseases surveillance (reporting incident cases, acute cases or rates per 100,000 population).
(d)  Reports and data that are incomplete (e.g. number tested not provided or below 20).
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ime–sex–region group and empirical priors for all epidemiological
arameters, generating posterior estimates of incidence, preva-
ence, remission, and mortality that are internally consistent. In
ur model, the empirical priors for incidence, remission, and mor-
ality were uninformative; thus the posterior was informed only by
revalence data. Like the empirical prior, the posterior models also
ncorporate linear time trends, ﬂexible age patterns, and offsets for
ata on males. Applying region-speciﬁc population ﬁgures for 1990
nd 2005, age- and region-speciﬁc HBsAg prevalence was used to
alculate the absolute number of individuals chronically infected
ith HBV.
For  the purpose of generating endemicity maps, endemicity lev-
ls of HBsAg were deﬁned as low (<2%), lower intermediate (2–4%),
igher intermediate (5–7%) and high (≥8%). HBsAg infection lev-
ls have traditionally been described according to three categories
f endemicity indicating the proportion of the population being
eropositive for HBsAg [8,14]. However, given that there are regions
ery close to low endemicity (<2%) (e.g. 2.0% prevalence among chil-
ren in Western Europe and Central Latin America in 2005) and
thers rather close to high endemicity (≥8%) (e.g. 7.8% prevalenceamong  adults in Eastern Asia in 2005) the split of the intermediate
category better reﬂects regional differences and their implications.
3. Results
We  identiﬁed 396 studies of HBsAg prevalence after applying
all inclusion and exclusion criteria. To illustrate global endemicity,
estimated and categorized HBsAg prevalence in 2005 is shown in
Map  1 for children (5–9 years) and in Map  2 for adults (19–49 years)
applying world population age weights.
The pattern of age-speciﬁc HBsAg prevalence varied greatly by
region and the trend of a decreasing prevalence with age was more
evident in 1990 as compared to 2005, where some regions, e.g.
South East Asia showed an exceptional increase with age. For most
regions, predominantly Tropical Latin America, West sub-Saharan
Africa, Australasia, and North Africa, Figs. 2–5 indicate an overall
decrease in HBsAg prevalence between 1990 and 2005. East Asia
and Western Europe experienced some increase.
Global differences between males and females were small,
although females had a lower overall HBsAg prevalence of 3.5% in
J.J. Ott et al. / Vaccine 30 (2012) 2212– 2219 2215
Map 1. Map  for children.
Map  2. Map for adults.
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Figs. 2–5. HBsAg seroprevalence by region and age-group for males and females separately, 1990 and 2005.
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Table 1
Overview: Global HBsAg and people chronically infected.
Year Males Females Both
Persons HBsAg positive Prevalence Persons HBsAg positive Prevalence Persons HBsAg positive Prevalence
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l1990 118 million 4.4 105 million
2005  127 million 3.9 113 million
005 compared to 3.9% in males. We  estimated 240 million people
hronically infected worldwide in 2005 (Table 1).
.1.  HBsAg prevalence by GBD world region
Tables 2–5: Web  Annex 3)
HBV prevalence was most common in sub-Saharan regions of
frica. Western sub-Saharan African countries had some of the high-
st age-speciﬁc HBsAg prevalence in the world reaching up to 12%
mong children and adolescents in the age-groups up to 19 years in
990. Although there was a decrease in 2005, the region continued
o have high HBV endemicity, which is more pronounced among
ales.
An increase in chronic HBV infection among younger age-groups
0–14 years) occurred in Southern sub-Saharan Africa in 2005 com-
ared to 1990 that resulted in age-speciﬁc prevalence of 8–9%
mong young females. Also Eastern sub-Saharan African countries
aced an increase in the youngest ages and almost no change in
ther age-groups. In 2005, prevalence peaked at approximately 7%
n 0–4 years aged boys and girls and declined with age in this region.
A decrease in prevalence was evident in Central sub-Saharan
frica which transitioned from high endemicity among younger
ndividuals (age-groups up to 34 years) in 1990 into intermediate
ndemicity across all ages in 2005.
North Africa and the Middle Eastern region showed lower
ntermediate HBsAg endemicity across all age-groups in 2005.
revalence decreased from 1990 to 2005, particularly among males
p to 34 years.
The  prevalence in high-income countries of North America
Canada and the United States) was low and declined among both
exes and across all ages between 1990 and 2005. Males had higher
BsAg positivity than females in both periods, peaking in the male
–4 years age-group at 2.71% and 2.14% in 1990 and 2005, respec-
ively. The oldest ages (65+ years) showed the lowest prevalence of
pproximately 1% in 2005.
Both  Tropical Latin America and Central Latin America demon-
trated a strong decrease in HBsAg prevalence between 1990 and
005. Tropical Latin America changed from an intermediate into a
ow endemicity region. Where 0–9 year aged boys had a higher
ntermediate endemicity of over 5% in 1990, HBsAg prevalence
as only 1.6% in 2005. Similarly, in Central Latin America preva-
ence has halved in this period and most adult age-groups shifted
o a low endemicity level in 2005. Other Latin American regions
uch as Andean Latin America and Southern Latin America showed a
ecreasing prevalence by age but relatively constant intermediate
ndemicity levels. A slight decline in prevalence from 1990 to 2005
mong Andean Latin Americans was paralleled by an increase in
BsAg prevalence in Southern Latin America.
HBV chronic infection rates in Caribbean children and adoles-
ents aged 0–19 years ranged from 4.3% to 5.4% and was  fairly
onstant over time. HBsAg prevalence decreased with age.
In  the island nations of the Paciﬁc and Indian Oceans (Ocea-
ia), HBsAg was highly endemic among men  and women  in 1990,
eaking at approximately 10% in men  aged 10–34. The decrease
n prevalence up to 2005 led to a shift into a higher intermediate
ndemicity level among the age-groups up to age 54 and into a
ower intermediate endemicity level in older adults (55+).4.0 223 million 4.2
3.5 240 million 3.7
Among the European regions, seroprevalence of HBsAg showed
consistently low prevalence in Western Europe. This was  particu-
larly true for females who had prevalence below 2% throughout the
time periods. Nevertheless, between 1990 and 2005, an increase in
both sexes was observed that led to a change from initially low
endemicity in young males to a low-intermediate endemicity level
in 2005; this was accompanied by a decrease in prevalence in the
older individuals (65+ years). Central and Eastern European chil-
dren had a higher intermediate HBsAg endemicity in 1990, which
decreased in 2005. Older Central European females in particular
demonstrated a strong HBsAg prevalence decrease up to 2005.
Prevalence in infant and young girls declined from 6% in 1990 to
3% in 2005 in this region. In contrast, Eastern European countries
did not experience as strong a reduction in HBsAg prevalence in the
youngest age-groups. In both Central and Eastern Europe the age
group 0–9 years remains the most affected by HBsAg infection.
Among  all Asian regions, East Asia had the highest prevalence of
HBV infection and there was  not much of a change between 1990
and 2005 apart from a slight decrease in children and an increase
in all age-groups above 25 years in 2005 as compared to 1990. In
1990, prevalence decreased in both sexes with age, but increased
with age in 2005 and showed the highest prevalence of over 8%
among males aged over 35 years. Generally, endemicity remains
at high or close to a high endemicity in this region, which is par-
ticularly true for males. Intermediate HBsAg endemicity was also
estimated for Central Asia, which includes the Caucasus and central
Asian countries. A small decrease was observed between 1990 and
2005 but Central Asian children and younger adults had an HBsAg
prevalence of around 5% in 2005. In South Asia, approximately 3%
of the population up to age 45 was HBsAg positive with a decrease
in older individuals who demonstrated a low prevalence in 2005.
Unlike other Asian regions, South East Asia experienced a strong
reduction in HBsAg prevalence between 1990 and 2005, particu-
larly in the young age groups of 0–14 years that had prevalence
levels of 1.2–1.4% in 2005. In contrast, South East Asian adults
appeared to continuously have higher-intermediate HBsAg preva-
lence of 5% to over 6% in 2005. The pattern of an increasing
prevalence with age was very pronounced in 1990 and rather
exceptional compared to the other regions.
Some reduction in HBsAg prevalence between 1990 and 2005
occurred also in high income Asian Paciﬁc countries including Japan,
the Republic of Korea, and Singapore. The middle ages (25–54) were
the most affected age groups but overall, endemicity remained at
an lower intermediate level of approximately 4% in 2005. Interest-
ingly, in 1990 the oldest age-groups of over 75 years had the highest
prevalence among all age-groups.
Australasian  countries experienced a reduction in HBsAg preva-
lence and were categorized as a lower intermediate endemicity
region in 2005. Males of all age-groups had prevalence in the range
of 4% in 2005 whereas 2–3% of females up to age 55 were affected
by chronic HBV infection with a sharp increase in the oldest age-
groups.4. Discussion
We  found a very large burden of HBsAg infection in all sub-
Saharan African regions, East Asia and, to a lesser extent, in Oceania
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nd Andean Latin America. Most other regions with high and
iddle income showed a mix  of lower and higher intermedi-
te HBV endemicity. Only a few regions demonstrated prevalence
elow 2% throughout most age-groups. Among these were Tropical
atin America, Central Latin America, North America and Western
urope. There was an overall decrease in HBsAg prevalence from
990 to 2005 in younger age-groups, which may  be closely related
o widespread hepatitis B immunization, particularly in low income
egions. Signiﬁcant decreases in HBsAg prevalence due to immu-
ization were reported from African countries such as the Gambia
15,16] and Senegal [17]. However, the infection remains extremely
revalent in sub-Saharan Africa and the attributable HBV-related
isease burden can be expected to remain high. This is also reﬂected
n a high mortality from primary liver cancer, one sequelae of
hronic HBV infection and the most frequent cause of cancer deaths
mong men  in this region [18].
The observed decreases in HBsAg prevalence in North America
nd Europe were temporally associated with increased hepatitis
 vaccine coverage rates [19], improved screening of blood prod-
cts and increased availability of safe injection materials [20,21].
he generally low HBsAg endemicity levels in these countries are
aralleled by a steady decline in reported cases of acute hepatitis B
22,23]. On the other hand, the large number of individuals infected
ith HBV inﬂuences the number of liver cirrhosis and cancer cases
n many world regions including high income countries [24] and
ighlights a need for screening and surveillance programs to iden-
ify chronically infected individuals and thereby prevent further
ransmission as well as to provide opportunities for secondary and
ertiary prevention [3].
Asian countries, for example those in the GBD South East and
ast Asian regions, have also has experienced dramatic increases
n coverage of routine infant hepatitis B vaccine that were accom-
anied by a reduction in HBsAg prevalence. The impact of this
ecrease in HBsAg prevalence was also measurable in a substantial
eduction in the HBV-related disease burden in countries that were
ighly endemic in the past e.g. Taiwan [25,26] and China [27,28].
Strengths  of this study include the extensive systematic litera-
ure review and the use of an empirical Bayesian hierarchical model
o estimate region-speciﬁc HBsAg prevalence and endemicity and
o subsequently calculate the absolute number of people being
hronically infected with the HBV.
This study has a number of limitations. Observed HBsAg preva-
ence data are lacking in some regions and the quality of studies
eporting these data is often low. Middle- and low income regions,
.g. Oceania, Central Asia, and Andean Latin America had a lim-
ted evidence base or studies were concentrated on one country
s is the case with India as part of the South Asian region or
hailand located in the South East Asian region. Accordingly, sim-
lations of prevalence may  lead to potential underestimation of
he true regional proﬁle, particularly if studies were more likely
o be conducted in countries with higher economic standards and
etter research infrastructure. To address issues of representa-
iveness, grey and non-English literature should be considered in
uture studies and there is a need for generating more high qual-
ty data from low resource settings. Most high quality studies were
onducted in high income countries, for example the Western Euro-
ean region. Nationally representative, population-based studies
eporting HBsAg prevalence were only available from the US.
Another  limitation is related to factors that were not considered
n our analysis such as genotype information. It is known that viral
enotypes vary between and within countries, depending on the
opulations at risk and their geographical origin. Very few HBV
revalence studies report on genotype and the genotype-speciﬁc
BV distribution by country has not been sufﬁciently studied. As
 result, we did not adjust for this information, which might be
rucial given the fact that some genotypes are associated with more(2012) 2212– 2219
severe  disease or clinical response to treatment [29–31]. Similarly,
the laboratory method used to detect HBsAg was  only reported in
a few studies and we  did not consider this factor in the analysis,
which could impact the comparability of HBsAg prevalence across
studies.
Since the overall objective of this study is to provide a regional
picture of HBV prevalence, the results do not capture the potential
heterogeneity that exists between sub-populations within a coun-
try. It should be noted that some low endemicity areas in Western
Europe and North America face great intra-country variation with
higher prevalence and higher hepatitis-related mortality among
migrants [32–35] and additional country-speciﬁc data would be
crucial for comprehensively guiding national hepatitis B prevention
and control programs and targeting most vulnerable population
groups.
Prevalence data obtained from systematic reviews and model-
ing should be interpreted conservatively. Descriptive epidemiolog-
ical research conducted in high income areas may  generally focus
more on marginalized and higher risk populations whereas studies
from low income regions may  focus on urban and higher educated
populations that experience lower infection rates than those living
in poorer areas. As a result, the prevalence of chronic HBV infec-
tion reported in this study could be overestimated for high income
regions and underestimated for low income regions. This would,
however, increase the estimated differences between these regions
and support our ﬁndings.
There  is a need for systematically collected and population-
based HBV infection data. Data on other markers of HBV such as
HBeAg and anti-HBc are also needed to describe current and future
HBV-related disease burden.
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